The prediction of treatment response in many neuropsychiatric disorders would be facilitated by easily accessible biomarkers.
Using flow cytometry, we herein demonstrate correlations between early reduction in p11 levels in natural killer (NK) cells and monocytes, and antidepressant response to citalopram in patients with major depressive disorder (MDD).
The multifunctional protein p11 amplifies serotonin receptormediated signaling 1, 2 and regulates gene transcription. 3, 4 P11 levels are reduced in neurons of the frontal cortex, nucleus accumbens and hippocampus from depressed individuals and suicide victims. 1, 5 Neuronal p11 levels are also reduced in animal models of depression, 1 but are upregulated by various antidepressant treatments, including selective serotonin reuptake inhibitors. 1, 6 P11 knockout mice show a depressionlike phenotype and reduced behavioral improvements and neurogenesis in response to antidepressant regimens. 6, 7 Conversely, overexpression of p11 in mice mimics the behavioral phenotype seen after antidepressant treatment. 1 Here, we examined the possibility that p11 in white blood cells could serve as a biomarker of antidepressant response using the selective serotonin reuptake inhibitor, citalopram.
After giving informed consent, 26 patients with MDD in a current major depressive episode were recruited at the National Institute of Mental Health (for details see Supplementary Information). Their average (s.d.) age was 36.9 ± 10.4, and there were 11 females and 15 males. The patients were screened and diagnosed using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition and Structured Clinical Interview for DSM-IV. Severity of depression was assessed using the Montgomery--Åsberg Depression Rating Scale (MADRS) and the Quick Inventory of Depressive Symptomatology-C16 (QIDS). Subjects were given a daily dosage of citalopram, doses were increased over time (see Supplementary Information), but were held constant for the week before blood was drawn. Subjects were evaluated on a weekly basis for 8 weeks. Peripheral blood mononuclear cells (PBMCs) were prepared at baseline and following 2 and 8 weeks of citalopram treatment; 14 patients had all three sets of blood collected. A separate group of nine patients with MDD was recruited at UT Southwestern in Dallas and assessed using the Inventory of Depressive Symptomatology (IDS) (for details see Supplementary Information). They were treated with citalopram and had blood collected at baseline and following 1 and 12 weeks; six patients had all three sets of blood collected. The protocols were approved by local IRBs. The PBMC samples were coded at the NIMH and UT Southwestern, respectively. All subsequent analysis and quantifications of p11 were done blind at Karolinska Institutet. PBMCs were isolated and stored at − 80°C in 90% FCS/ 10% DMSO. For analysis, PBMCs were thawed, washed in PBS, permeabilised and incubated for 30 min at +4°C with anti-human p11 (148; 2.5 μg ml − 1 ; BD Biosciences, Stockholm, Sweden) or isotype control mouse IgG1 monoclonal antibodies. The bound antibody was detected by PE-conjugated antimouse antibody (Dako, Glostrup, Denmark). To distinguish between NK cells, monocytes and T cells, surface staining (CD3, CD14 and CD56; BD Biosciences) was performed after blocking of an unbound antimouse antibody using 1% normal mouse serum (Sigma, Stockholm, Sweden). After labeling, cells were subjected to flow cytometry analysis to detect p11 levels in gated populations of white blood cells (Supplementary Figure S1 ). Analyses were done using FlowJo software (Tree Star, Ashland, OR, USA). Statistical analyses used Pearson's correlation test and determined 95% confidence intervals (GraphPad Prism5, La Jolla, CA, USA).
Flow cytometry analysis of PBMCs showed that p11 was present in essentially all CD3-CD56+ NK cells (Figure 1a Figure S4) .
As animal studies have shown that antidepressants increase p11 in neurons in the brain, 4 it appears paradoxical that a decrease in p11 in white blood cells should be associated with antidepressant response. Future studies will need to examine whether antidepressants regulate p11 in microglia, which, like monocytes, are derived from myeloid precursors. Future clinical studies, using citalopram and other antidepressants with larger sample sizes, need to be carried out. If such studies confirm the results of the present investigation, early analyses of p11 levels would guide clinicians in deciding whether treatment with a particular antidepressant should continue or whether it would be better to switch to another antidepressant therapy. We read with interest the systematic review and meta-analysis by Faroane et al.
CONFLICT OF INTEREST
1 of the association between the SLC6A3 3'UTR polymorphism and in vivo striatal dopamine transporter (DAT) binding measured using molecular imaging studies. They found that the 9R allele of dopamine active transporter (DAT) gene (SLC6A3) was associated with increased DAT activity in human adults. This conclusion was based on the single-photon emission computed tomography and positron emission tomography (PET) studies. However, we have a methodological concern that has a major implication for some of their findings. The findings from the PET imaging were based on two studies that used two different ligands 1 (Figure 2 ). The analysis, as illustrated in the funnel plot 1 (Figure 2) , shows that the standardiazed mean differences from different striatal subregions within the same study were treated as independent measures. Clearly the DAT genotype is the same for a given subject irrespective of the region, and as such these are not independent measures. Furthermore, molecular imaging measures of dopamine in striatal subregions are highly correlated 2 and not independent due to partial volume effects. 3, 4 For these two reasons the analysis appears to have violated the requirement in a meta-analysis for measures to be independent. 5 Additionally, while it is possible to combine the effect sizes from meta-analysis with two or more studies, at least N = 6 has been suggested as a minimum below which findings are likely to be unreliable. 6 In meta-analysis of n = 2 studies, heterogeneity analyses are likely to underestimate the variance among studies. 7 Finally, the inconsistencies between results of imaging studies may also be due to biological differences in the DAT protein expression, as amine transporters are post-transcriptionally regulated by various kinases and phosphatases. 8, 9 For these reasons we are concerned that the conclusions may not be justified 1 and welcome clarification.
Response to Selveraj et al. Our recent meta-analysis published in Molecular Psychiatry 1 analysed two positron emission tomography (PET) studies and ten single photon emission tomography (SPECT) studies. We concluded that the 9R allele of the 3'UTR polymorphism of the dopamine transporter gene (SLC6A3) regulates dopamine activity in striatal brain regions independent of the presence of neuropsychiatric illness. A Letter to the Editor by Selveraj et al. 2 raised several questions about our work, which we would like to address.
Our meta-analysis presented PET results from the two extant studies. The Letter is concerned with the small number of studies. We agree with this concern, which is why we addressed it as a limitation in our paper. The Letter is also concerned that we used several potentially correlated measures from the same studies. Although this issue would not bias our estimates of the standardized mean difference (SMD) effect size or the confidence intervals for each study, it could have affected our significance levels for the pooled analyses. We allay this latter concern with three observations. First, in Figure 2 from our paper readers can see that all of the 11 PET measures had SMDs >1.0, suggesting that the 9R allele is associated with increased dopamine transporter (DAT) binding. Second, we re-analysed data separately for the two brain regions that were included in both PET studies. In these pooled analyses, the SMDs are statistically significant for both caudate (SMD = 0.38, z = 2.4, P = 0.017) and putamen (SMD = 0.33, z = 2.1, P = 0.04). Third, our conclusions are consistent with the conclusions reported by each of the PET studies.
3,4 Thus, we stand by our original conclusions but refer readers of this letter to our paper for an understanding of factors that limit the strength of these conclusions.
Finally, the Letter also notes that 'inconsistencies between results of imaging studies may also be due to biological differences in the DAT protein expression, as amine transporters are post-transcriptionally regulated by various kinases and phosphatases.' We agree (as is clear in our manuscript's Discussion) that the regulation of DAT expression is complex. We welcome further research to clarify this issue.
